Ventripoint increases financing to $1-million

Executive Summary

• Ventripoint Diagnostics Ltd. is doubling the size of its previously announced non-brokered private placement from $500,000 to $1,000,000 due to strong investor demand.
• The offering remains subject to approval by the TSX Venture Exchange.
• Proceeds will be utilized to support commercialization activities, manufacturing scale-up, regulatory submissions, and general operational requirements.

Key Details

• Transaction Size: Increased from $500,000 to $1,000,000.
• Instrument Structure: Each unit consists of one common share and one common share purchase warrant.
• Warrant Terms:
  • Exercise Price: 13 cents per common share.
  • Duration: 24 months from closing.
  • Acceleration Clause: The company reserves the right to accelerate the warrant expiry period upon 30 days' notice if the common shares trade at or above 26 cents on the TSX-V for 10 consecutive days (including non-trading days).
• Finder’s Fees: The corporation may pay cash finders' fees and issue common share purchase warrants equivalent to up to 8% of the gross proceeds.
  • Finder’s Warrant Exercise Price: 13 cents per common share.
  • Finder’s Warrant Duration: 24 months from closing.
• Use of Proceeds: Critical commercialization activities, manufacturing scale-up, continued regulatory submissions, and operational requirements.
• Hold Period: All securities issued are subject to a hold period of four months plus one day from the date of closing.
• Regulatory Status: Subject to TSX Venture Exchange approval.

Notable Quotes

• No direct quotes from management were included in the provided text.